ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)Susana Banerjee, James Stewart, Nuria Porta, Christy Toms, Alexandra Leary, Stephanie Lheureux, Saira Khalique, Jeremy Tai, Ayoma Attygalle, Katherine Vroobel, Christopher J Lord, Rachael Natrajan, Judith Bliss
13 September 2021
BIOPSAR study: ultrasound-guided pre-operative biopsy to assess histology of sarcoma-suspicious uterine tumors: a new study protocolStamatios Petousis, Sabrina Croce, Michel Kind, Chrysoula Margioula-Siarkou, Guillame Babin, Caroline Lalet, Dennis Querleu, Anne Floquet, Marina Pulido, Frederic Guyon
29 September 2021
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)Lucia Musacchio, Vanda Salutari, Sandro Pignata, Elena Braicu, David Cibula, Nicoletta Colombo, Jean Sebastien Frenel, Flora Zagouri, Vittoria Carbone, Viola Ghizzoni, Serena Giolitto, Elena Giudice, Maria Teresa Perri, Caterina Ricci, Giovanni ScambiaSee the full list of authors
4 October 2021
Determining post-operative morbidity and mortality following gynecological oncology surgery: protocol for a multicenter, international, prospective cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative—GO SOAR)Faiza Gaba, Nicolò Bizzarri, Paul Kamfwa, Allison Saiz, Oleg Blyuss, Shantini Paranjothy, Pedro T Ramirez, David Cibula, , on behalf of the GO SOAR Team, Mohamedraed Elshami, Mahmoud Saad, Ahmed Nafea, Muhammed Elhadi, Alaa IsmailSee the full list of authors
6 September 2021
Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial)Claudia Marchetti, Riccardo Tudisco, Vanda Salutari, Antonella Pietragalla, Giovanni Scambia, Anna Fagotti
15 June 2021
Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence; AGO-OP.6)Günter Emons, Jae-Weon Kim, Karin Weide, Nikolaus de Gregorio, Pauline Wimberger, Fabian Trillsch, Boris Gabriel, Dominik Denschlag, Stefan Kommoss, Mustafa Aydogdu, Thomas Papathemelis, Martina Gropp-Meier, Mustafa-Zelal Muallem, Cristin Kühn, Andreas MüllerSee the full list of authors
5 July 2021
TRAINING-Ovary 01 (connecTed pRehabiliAtIoN pelvIc caNcer surGery): multicenter randomized study comparing neoadjuvant chemotherapy for patients managed for ovarian cancer with or without a connected pre-habilitation programEric Lambaudie, Cécile Bannier/Braticevic, Charlène Villaron/Goetgheluck, Christophe Zemmour, Jean-Marie Boher, Patrick Ben Soussan, Jihane Pakradouni, Clement Brun, Leonor Lopez Almeida, Patricia Marino
1 December 2020
Facilitated cascade testing (FaCT): a randomized controlled trialRoni Nitecki, Haley A Moss, Catherine H Watson, Diana L Urbauer, Alexander Melamed, Karen H Lu, Steven M Lipkin, Kenneth Offit, Jose Alejandro Rauh-Hain, Melissa K Frey
18 December 2020
A randomized phase III trial of adjuvant chemotherapy versus concurrent chemoradiotherapy for postoperative cervical cancer: Japanese Gynecologic Oncology Group study (JGOG1082)Akiko Furusawa, Munetaka Takekuma, Keita Mori, Tomoka Usami, Eiji Kondo, Shin Nishio, Koji Nishino, Yuichiro Miyamoto, Ryoichi Yoshimura, Miho Watanabe, Mikio Mikami, Takayuki Enomoto
4 March 2021
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA TrialAntonio Gonzalez Martin, Luisa Sanchez Lorenzo, Nicoletta Colombo, René dePont Christensen, Florian Heitz, Mihai Meirovitz, Frederic Selle, Toon van Gorp, Nuria Alvarez, Javier Sanchez, Carmen Marqués
14 December 2020